AUS
NZ
UK
CA
USA
IND
CSL Limited (ASX: CSL), one of Australia's leading healthcare companies, has faced challenges in recent months, resulting in a decline in its share price. Concerns over a slower margin recovery and the emergence of Ozempic as a potential treatment for kidney disease have contributed to a nearly 27% drop from its 52-week high. However, an interesting development has recently caught the attention of investors. A change of director's interest notice reveals that independent non-executive director Dr. Megan Clark AC increased her holdings in CSL through an on-market trade. This insider purchase suggests a positive outlook for the company.
Insider Purchase:
Dr. Megan Clark AC acquired 210 CSL shares on 20 October, with an average purchase price of approximately $237.81 per share. The total consideration for this purchase amounted to just under $50,000. This transaction increased her direct holding in CSL to a total of 3,683 shares. Additionally, Dr. Clark holds 1,281 shares indirectly and has 290 share rights.
Analyst Support:
Citi, a prominent financial institution, has reaffirmed its buy rating for CSL. Moreover, the brokerage firm has set a price target of $325.00, implying a potential upside of 37% from the current share price. To put this into perspective, if CSL shares were to reach this target, the 210 units acquired by Dr. Clark would have a market value of $68,250, significantly exceeding her purchase price of approximately $50,000.
Citi's assessment of CSL's outlook and valuation is positive. The company remains confident in its ability to generate double-digit earnings per share (EPS) growth over the medium term, aligning with consensus and Citi forecasts of 14% to 15% EPS compound annual growth rate over FY23-28. Additionally, CSL is trading at a price-to-earnings ratio (PE) FY25 of approximately 23x, representing a 5x discount compared to its historical average.
Conclusion:
The recent insider purchase by Dr. Megan Clark AC, combined with Citi's favorable outlook and valuation of CSL, offers an encouraging signal for investors. While CSL has faced recent challenges, the insider's confidence in the company's shares may suggest that the current price level presents an attractive buying opportunity, aligning with Citi's positive sentiment regarding the healthcare stock.
